Trial results

UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

NCT07163624 on ClinicalTrials.gov · last registry update 2026-05-07

Finished 21 November 2025, after enrolling 211 people. Primary outcome, as filed: Change From Baseline in HbA1c at Week 24. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

The United Bio-Technology (Hengqin) Co., Ltd.

Sponsor type

Industry

Enrollment

211

Started

2025-03-22

Primary completion

2025-11-21 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in HbA1c at Week 24

Conditions studied

Type 2 Diabetes Mellitus (T2DM)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.